Non‐erythropoietic erythropoietin‐derived peptide protects mice from systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is an autoimmune disease, which results in various organ pathologies. However, current treatment towards SLE is suboptimal. Erythropoietin (EPO) has been shown to promote SLE recovery, but clinical application can be limited by its haematopoiesis‐stimulating effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Bo, Jiang, Juntao, Luo, Bangwei, Zhu, Wen, Liu, Yuqi, Wang, Zhishang, Zhang, Zhiren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010693/
https://www.ncbi.nlm.nih.gov/pubmed/29570934
http://dx.doi.org/10.1111/jcmm.13608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010693/
https://www.ncbi.nlm.nih.gov/pubmed/29570934
http://dx.doi.org/10.1111/jcmm.13608

Ejemplares similares